Aveo Pharmaceuticals and Biogen Idec (NASDAQ:[[ticker:BIIB]]), both based in Cambridge, MA, have struck a development deal related to Cambridge, MA-based Aveo’s program to discover antibody drugs that target a cellular receptor known as ErbB3, according to Aveo. The cellular receptor is found in abundance on several types of cancer cells and is believed to promote tumor growth. Aveo, which says the deal with Biogen involves the potential development of its ErbB3-targeting antibodies for treating cancer and other diseases, did not reveal financial details of the transaction.
Author: Ryan McBride
Ryan is an award-winning business journalist who contributes to our life sciences and technology coverage. He was previously a staff writer for Mass High Tech, a Boston business and technology newspaper, where he and his colleagues won a national business journalism award from the Society of American Business Editors and Writers in 2008. In recent years, he has made regular TV appearances on New England Cable News.
Prior to MHT, Ryan covered the life sciences, technology, and energy sectors for Providence Business News. He graduated with honors from the University of Rhode Island in 2001 with a bachelor’s degree in communications. When he’s not chasing down news, Ryan enjoys mountain biking and skiing in his home state of Vermont.
View all posts by Ryan McBride
